



An Update on Fleas, Flea-Borne Diseases, and Flea Control

Brian Herrin, DVM, PhD, DACVM (Parasitology)

University of Tennessee College of Veterinary Medicine, Knoxville, Tennessee

Abstract

Fleas are blood-feeding arthropods that can infest a wide variety of hosts. *Ctenocephalides felis*, the cat flea, is the most common flea species found on dogs and cats worldwide, as well as the most medically important in the veterinary setting. This article focuses on *C felis*, the diseases associated with flea feeding, and available products that both eliminate flea infestations on pets and break the flea life cycle in the environment.

Take-Home Points

- Flea allergy dermatitis remains one of the most common dermatologic issues in dogs and cats.
- Fleas transmit a variety of bacterial and parasitic pathogens, and proper flea control is key to eliminating these infections.
- Flea control products with a rapid residual speed of kill are necessary to eliminate fleas throughout the dosing period of a product.
- Due to the environmental burden of flea life stages, continuous flea control of 3-plus months is often needed to eliminate home infestation.
- Year-round flea control is recommended for dogs and cats in most of North America due to the extended seasonal occurrence of fleas.

The most common flea of domestic dogs and cats worldwide is *Ctenocephalides felis*, the cat flea (**FIGURE 1**).¹ In some countries, *Ctenocephalides canis* is more commonly found on dogs, but this species is rare in the United States.^{2,3} Other flea species that have been recovered from dogs and cats include *Pulex* species, *Xenopsylla cheopis*, and *Echidnophaga gallinacea*; however, this review primarily describes the veterinary importance of the cat flea and the effectiveness of current parasiticides in treating and/or preventing infestation.

Life Cycle

All fleas of veterinary importance have a similar life cycle that comprises 4 stages: egg, larva, pupa, and adult (go.navc.com/49D0ftK). The eggs, larvae, and pupae develop in the environment and rely on multiple environmental and host cues to continue development. Once in the pupal stage, adult fleas wait for the right combination of stimuli, including physical pressure, heat, and carbon dioxide, to emerge and seek a new host.⁴

After finding a host, adult cat fleas live, feed, and mate on their host, becoming permanent ectoparasites after feeding for approximately 24 hours.⁵ While fleas can be found feeding anywhere on the host, they are most likely to be recovered from the area covering the middle of the back to the base of the tail and extending laterally down the rear legs (“the flea triangle”) on dogs; on cats, they are more likely to be recovered from the head and neck region due to fastidious grooming.⁶

Many mammals can serve as the host for adult fleas, including several species of periurban wildlife, such as cats, dogs, skunks, opossums, raccoons, several rodent species, coyotes, and foxes. Therefore, infestation—and reinfestation—can be common in pets that have access to the outdoors. This risk underscores why effective flea control requires targeting adults on the host using products with a rapid residual speed of kill to prevent reproduction and environmental contamination while also breaking the life cycle in the environment.

Diseases Associated With Flea Feeding

The cat flea is the most medically important ectoparasite of cats and dogs, responsible for anemia,

flea allergy dermatitis (FAD), and the transmission of several pathogens of veterinary and human importance. On average, each female cat flea ingests ~14 μ L of blood each day; therefore, infestation with high numbers of fleas can result in a significant regenerative anemia.⁴

While flea feeding is associated with several dermatologic conditions, the most significant is FAD, an allergic condition caused by antigens in flea saliva.⁶ FAD is among the most common dermatologic conditions in dogs; therefore, effective flea prevention is key to the dermatologic workup of pruritic dogs. Some animals are highly sensitive and can have severe reactions to low numbers of fleas (<5 fleas); therefore, FAD should not be ruled out solely on the basis of finding few or no fleas on the animal during examination. In fact, animals that are reactive to fleas, especially cats, may have fewer fleas due to the intense grooming behaviors they exhibit.

Both FAD and flea feeding can induce a variety of dermatologic lesions such as alopecia, excoriations, erythema, papules, and crusts.⁶ These lesions can lead to secondary bacterial infections that exacerbate the condition of the animal. While addressing the entirety of the clinical case is important, highly effective flea control is the key to reducing dermatologic lesions caused by the presence of fleas (**FIGURE 2**).^{7,8}



FIGURE 1. Adult female *Ctenocephalides felis* flea. Note the distinct genal comb by the mouthparts (**black arrow**) and pronotal comb at the base of the head (**yellow arrow**), which help identify *C felis* from other fleas commonly found in North America.

Flea-Borne Pathogens

Bacterial Pathogens

C. felis has been implicated in the transmission of a variety of bacterial pathogens (TABLE 1). The most common bacterial species associated with the cat flea are *Rickettsia*, *Bartonella*, and *Mycoplasma*.⁹ *Yersinia pestis*, the causative agent of bubonic plague, and *Rickettsia typhi*, the causative agent of murine typhus, are primarily associated with *X. cheopis* (the Oriental rat flea) and rodents.

The cat flea maintains and transmits different pathogens in different ways. For *Rickettsia felis* and *Mycoplasma* species, the cat flea is a direct mechanical vector, transmitting the pathogen during feeding, while for *Bartonella* species, it passes infectious bacteria in its feces (stercorarian transmission), contaminating the environment.⁹⁻¹³



FIGURE 2. (A) Severe dermatologic lesions in a dog experiencing flea infestation. **(B)** The same dog 83 days post-treatment with an isoxazoline product. The photo was taken during a research study evaluating the ability of a selamectin-sarolaner product for cats and sarolaner product for dogs to eliminate home flea infestations and reduce dermatologic lesions associated with flea feeding.⁸

Bartonella Species

Bartonella species are the most commonly reported bacterial pathogens transmitted by the cat flea, with up to 85% of cats and 50% of dogs in the United States testing positive for antibodies.¹¹ These numbers reflect overall exposure; PCR testing of whole blood in the same study detected *Bartonella* species in 62.5% of the cats and 9.2% of the dogs.¹¹ The species identified included *Bartonella henselae*, *Bartonella koehlerae*, *Bartonella vinsonii*, and *Bartonella clarridgeiae*, each of which causes different diseases in dogs and cats.¹¹

The most notable of the *Bartonella* diseases is cat scratch fever, in which *B. henselae* residing on a cat's claws is introduced into human skin, leading to symptoms such as fever, enlarged lymph nodes, and even bacterial endocarditis.⁹⁻¹¹

Rickettsia Species

Domestic dogs are the likely reservoir host for *R. felis*, and the cat flea can both acquire the pathogen and transmit it to naïve hosts during feeding.^{9,12} The cat flea can also pass *R. felis* vertically to progeny for up to 12 generations without an infectious blood meal in that period. Thus, while the percentage of infected fleas can vary greatly depending on region (1% to 96%), the risk of infection from *C. felis* is ever present, even in laboratory-reared fleas.¹⁴

Mycoplasma Species

Canine and feline hemoplasmas are relatively common, with up to 52.4% of dogs and 66.7% of cats reported as PCR positive in various studies.¹³ *Mycoplasma haemocanis* and *Candidatus Mycoplasma haemominutum* are the most common hemoplasmas in dogs and cats, respectively, although several other species also affect both cats and dogs.¹³ While several hemoplasmas have been found in *C. felis*, flea feeding is not considered to be the primary transmission route, which is likely direct contact via fighting and biting.¹³

Treatment

Treatment of flea-borne bacterial infections often requires prolonged courses of antibiotics, especially for *Bartonella* infections, which may require combination therapy, including fluoroquinolone and doxycycline antibiotics.¹⁰

The use of flea control may be helpful in reducing the risk of infection or reinfection with flea-borne

pathogens; however, there is strong evidence supporting this for only *Bartonella* infections in cats. In laboratory studies, cats treated with a 10% imidacloprid–1% moxidectin topical solution were 100% protected from *B henselae* infection compared to controls.¹⁵ In another study, privately owned cats maintained on a 10% imidacloprid–4.5% flumethrin collar were significantly less likely to test positive for *Bartonella* species by PCR testing of whole blood than cats that were on no flea prevention.¹⁶ Despite the limited studies, year-round flea control is key to reducing flea exposure, thereby reducing pathogen exposure for pets and people.

Other Flea-Borne Pathogens

C felis is also the known vector for 2 other parasitic pathogens, *Dipylidium caninum* and *Acanthocheilonema reconditum*. *D caninum*, the flea tapeworm, infects dogs and cats via ingestion of a flea containing the infectious intermediate stage. Although diagnosis of *D caninum* infection was historically challenging, new antigen and PCR techniques have suggested that roughly 0.65% of dogs and 2.5% of cats are positive for this tapeworm.¹⁷ Fortunately, the intermediate stage (cysticercoid) within the flea requires the flea to feed for approximately 24 hours before becoming infectious. Therefore, animals on

highly effective flea control have been shown to be protected from infection.¹⁸ Given the recent reports of praziquantel resistance in *D caninum*, rapid and effective flea control is key to preventing infection or reinfection with this tapeworm.¹⁹

A reconditum is a filarial nematode that is transmitted by the cat flea and lives within the skin of dogs. Overall, *A reconditum* does not cause clinical disease in dogs, but it does produce microfilariae that enter peripheral circulation and must be differentiated from those of *Dirofilaria immitis*, the canine heartworm.²⁰ Veterinarians are encouraged to have any microfilariae seen in whole blood definitively identified by morphologic or molecular characteristics, especially in the face of a negative canine heartworm antigen test.

Treatment of Flea Infestations and Flea Control

Infestations with adult fleas can be treated using a variety of active ingredients and formulations for use on dogs and cats. These can be separated into 3 broad categories:

- Topical adulticide products that are approved by the U.S. Environmental Protection Agency
- Systemically acting adulticide products, which are predominantly approved by the U.S. FDA

TABLE 1 Common Bacterial Species Transmitted by *Ctenocephalides felis*

	PRIMARY RESERVOIRS	HOST EXPERIENCING DISEASE	CELL TYPE INFECTED	CLINICAL SIGN/DISEASE
<i>Rickettsia</i> species				
<i>Rickettsia felis</i>	Dogs, cats, other mammals	Humans	■ Endothelial cells	■ Fever
<i>R felis</i> –like organisms ^{9,10}				■ Myalgia
				■ Rash
				■ Eschar at the bite site
<i>Bartonella</i> species				
<i>Bartonella henselae</i> ^{9,11}	Cats	Humans, dogs, cats	■ Endothelial cells ■ Erythrocytes ■ Macrophages	■ Fever
<i>Bartonella clarridgeiae</i>	Cats			■ Swollen lymph nodes
<i>Bartonella koehlerae</i>	Cats			■ Endocarditis
<i>Bartonella quintana</i>	Humans			■ Neuroretinitis
				■ Encephalopathy
				■ Bacillary angiomatosis
<i>Mycoplasma</i> species				
<i>Mycoplasma haemofelis</i>	Cat	Cat	■ Erythrocytes	■ Fever
<i>Mycoplasma haemocanis</i> ^{9,12}	Dog	Dog		■ Jaundice
				■ Hemolytic anemia
				■ Splenomegaly

TABLE 2 Common Active Ingredients in Topical Flea Control Products⁵

ACTIVE INGREDIENTS	DRUG CLASS	MECHANISM OF ACTION	EXAMPLE PRODUCTS ^a (MANUFACTURER; SPECIES)
Imidacloprid	Neonicotinoid	Nicotinic acetylcholine receptor antagonist	Advantage II (Elanco; cats and dogs) ^b , Advantix (Elanco; dogs), Seresto (Elanco; cats and dogs) ^b
Dinotefuran			Vectra (Ceva; cats and dogs), Vectra 3D (Ceva; dogs)
Fipronil	Phenylpyrazole	Glutamate- and GABA-gated chloride-channel antagonist	Frontline (Boehringer Ingelheim; cats and dogs)
Permethrin	Synthetic pyrethroids	Axonal sodium-channel depolarization	Vectra 3D (dogs), Advantix (dogs)
Flumethrin			Seresto (cats and dogs)

GABA = γ -aminobutyric acid.^aMost of these compounds are available as generic products, and this list is not comprehensive.^bFormulations for both cats and dogs exist, but the final product may be species-specific depending on dose and the safety of other active ingredients.**TABLE 3 Common Active Ingredients in Systemic Flea Control Products^{5,19}**

ACTIVE INGREDIENTS	DRUG CLASS	MECHANISM OF ACTION	EXAMPLE PRODUCTS ^a (MANUFACTURER; SPECIES)
Nitenpyram	Neonicotinoid	Nicotinic acetylcholine receptor antagonist	Capstar (Elanco; cats and dogs) ^b
Selamectin	Macrocyclic lactones	Glutamate-gated chloride-channel antagonist	Revolution (Zoetis; cats and dogs) ^b
Spinosad	Spinosyns	Nicotinic acetylcholine receptor antagonist	Comfortis (Elanco; dogs)
Spinetoram			Cheristin (Elanco; cats)
Sarolaner	Isoxazolines	Glutamate- and GABA-gated chloride-channel antagonist	Revolution Plus (Zoetis; cats), Simparica (Zoetis; dogs)
Lotilaner			Credelio (Elanco; dogs), Credelio Cat (Elanco; cats)
Afoxolaner			Nexgard (Boehringer Ingelheim; dogs)
Esafoxolaner			Nexgard Combo (Boehringer Ingelheim; cats)
Fluralaner			Bravecto (Merck; dogs), Bravecto Plus (Merck; cats)

GABA = γ -aminobutyric acid.^aMost of these compounds are available as generic products, and this list is not comprehensive.^bFormulations for both cats and dogs exist, but the products may be species-specific depending on dose and the safety of other active ingredients within the final product.

- Insect growth regulators (IGRs) that vary in approval depending on formulation and use

Adulticidal Topical Products

Topically applied products are designed to be delivered via a spot-on, spray, or collar and have little to no systemic absorption or efficacy. These products, once applied, disperse across the body from the site of application; therefore, some time is needed to ensure full coverage, and some studies suggest they are not

evenly dispersed to distal sites such as the lower leg extremities.²¹ While fleas are exposed to the active ingredients immediately upon contact with the hair coat, these products should not necessarily be considered repellent in driving away fleas prior to feeding, especially given the rapid attachment and feeding seen in fleas.²²

Additionally, topical products are susceptible to degradation or dilution over time from exposure to sunlight, swimming, bathing, and shampooing, which

may affect drug efficacy, specifically at the end of the dosing period.²¹ **TABLE 2** highlights several of the most common topical active ingredients and products.

Adulticidal Systemic Products

Several drug classes can also be utilized as systemically acting flea control products, the newest of which are the isoxazolines (**TABLE 3**). Aside from nitenpyram, systemically acting products are all FDA labeled and require a veterinary prescription, in contrast to topical products. Systemic products, regardless of route of administration (oral, transdermal, injectable), are all systemically absorbed and are effective when fleas ingest the blood meal.^{21,23}

Despite requiring fleas to feed, many of the systemic products are highly effective and maintain a rapid speed of kill throughout the dosing period. This high speed of kill allows the systemic products to even control FAD in allergic dogs.^{7,8} The isoxazoline products have become the most commonly prescribed options for labeled flea and tick control and are now found in combination formulas that also have labeled efficacy against heartworms and some intestinal helminths, depending on formulation.

Insect Growth Regulators

IGRs (also known as insect development inhibitors) such as methoprene, pyriproxyfen, and lufenuron are commonly added to products to disrupt the flea life cycle and reduce environmental burdens more rapidly.⁵ They work either as juvenile hormone mimics (methoprene and pyriproxyfen) or as chitin inhibitors (lufenuron) that disrupt successful molting or egg development. Historically, these were helpful in combination with products that did not have a rapid speed of kill and allowed some eggs to be produced prior to adult flea death. The IGRs work by disrupting the development of immature stages and preventing eggs and larvae from maturing into reproducing adults, thus providing a secondary point to break the life cycle.⁵ In the future, IGRs will likely still play a key role in flea control, as combining an IGR with an adulticidal compound decreases the likelihood of developing resistance.

Summary

Despite decades of effective ectoparasite control for cats and dogs, the cat flea continues to be a major issue in veterinary medicine. Year-round compliance with highly effective flea control is key to preventing home infestations, reducing FAD, and decreasing the risk of flea-borne diseases to people and pets. **TVP**

References

1. Rust MK. The biology and ecology of cat fleas and advancements in their pest management: a review. *Insects*. 2017;8(4):118. doi:10.3390/insects8040118
2. Ahn KS, Huh SE, Seol SW, Kim HJ, Suh KH, Shin S. *Ctenocephalides canis* is the dominant flea species of dogs in the Republic of Korea. *Parasit Vectors*. 2018;11(1):196. doi:10.1186/s13071-018-2769-9
3. Beugnet F, Soll M, Bouhsira E, Franc M. Sustained speed of kill and repellency of a novel combination of fipronil and permethrin against *Ctenocephalides canis* flea infestations in dogs. *Parasit Vectors*. 2015;8:52. doi:10.1186/s13071-015-0680-1
4. Dryden MW, Rust MK. The cat flea: biology, ecology and control. *Vet Parasitol*. 1994;52(1-2):1-19. doi:10.1016/0304-4017(94)90031-0
5. Blagburn BL, Dryden MW. Biology, treatment, and control of flea and tick infestations. *Vet Clin North Am Small Anim Pract*. 2009;39(6):1173-1200. viii. doi:10.1016/j.cvsm.2009.07.001
6. Lam A, Yu A. Overview of flea allergy dermatitis. *Compend Contin Educ Vet*. 2009;31(5):E1-E10.
7. Dryden MW, Canfield MS, Herrin BH, et al. In-home assessment of flea control and dermatologic lesions in dogs provided by lotilaner (Credelio®) and spinosad (Comfortis®) in west central Florida. *Vet Parasitol*. 2019;276S:100009. doi:10.1016/j.vpoa.2019.100009
8. Dryden MW, Herrin BH, Canfield MS, et al. Evaluation of a topical sarolaner-selamectin combination to control flea populations on naturally infested cats in private residences in West Central Florida. *Vet Parasitol*. 2020;283:109172. doi:10.1016/j.vetpar.2020.109172
9. Moore CO, André MR, Šlapeta J, Breitschwerdt EB. Vector biology of the cat flea *Ctenocephalides felis*. *Trends Parasitol*. 2024;40(4):324-337. doi:10.1016/j.pt.2024.02.006
10. Taber R, Pankowski A, Ludwig AL, Jensen M, Magsamen V, Lashnits E. Bartonellosis in dogs and cats, an update. *Vet Clin North Am Small Anim Pract*. 2022;52(6):1163-1192. doi:10.1016/j.cvsm.2022.06.006
11. Álvarez-Fernández A, Breitschwerdt EB, Solano-Gallego L. *Bartonella* infections in cats and dogs including zoonotic aspects. *Parasit Vectors*. 2018;11(1):624. doi:10.1186/s13071-018-3152-6
12. Blanton LS, Walker DH. Flea-borne rickettsioses and rickettsiae. *Am J Trop Med Hyg*. 2017;96(1):53-56. doi:10.4269/ajtmh.16-0537
13. Tasker S. Hemotropic mycoplasma. *Vet Clin North Am Small Anim Pract*. 2022;52(6):1319-1340. doi:10.1016/j.cvsm.2022.06.010
14. Reif KE, Macaluso KR. Ecology of *Rickettsia felis*: a review. *J Med Entomol*. 2009;46(4):723-736. doi:10.1603/033.046.0402
15. Bradbury CA, Lappin MR. Evaluation of topical application of 10% imidacloprid-1% moxidectin to prevent *Bartonella henselae* transmission from cat fleas. *JAVMA*. 2010;236(8):869-873. doi:10.2460/javma.236.8.869
16. Greco G, Brianti E, Buonavoglia C, et al. Effectiveness of a 10% imidacloprid/4.5% flumethrin polymer matrix collar in reducing the risk of *Bartonella* spp. infection in privately owned cats. *Parasit Vectors*. 2019;12(1):69. doi:10.1186/s13071-018-3257-y

Zenalpha®

(medetomidine and vatinoxan hydrochlorides injection)

Sedative, Analgesic

For Use in Dogs Only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.**BRIEF SUMMARY: (for full prescribing information, see package insert)****DESCRIPTION:** Zenalpha is a combination of medetomidine and vatinoxan hydrochlorides. Each mL of Zenalpha contains 0.5 mg medetomidine hydrochloride, 10 mg vatinoxan hydrochloride, 32.5 mg mannitol (USP), 4.16 mg citric acid monohydrate (USP), 1.8 mg methylparaben (NF), 0.2 mg propylparaben (NF).**INDICATION:** Zenalpha is indicated for use as a sedative and analgesic in dogs to facilitate clinical examination, clinical procedures and minor surgical procedures.**CONTRAINDICATIONS:** Do not use Zenalpha in dogs with cardiac disease, respiratory disorders, shock, severe debilitation, that have hypoglycemia or are at risk of developing hypoglycemia, or are stressed due to extreme heat, cold or fatigue.

Zenalpha is contraindicated in dogs with a known sensitivity to medetomidine or vatinoxan.

WARNINGS:**Human User Safety Warnings**

Not for use in humans. Keep this and all medications out of reach of children and pets.

Avoid skin, eye or mucosal contact. Absorption of the active ingredients is possible following exposure via the skin, eye or mucosa. If symptoms occur, seek the advice of a physician.

In case of accidental oral intake or self-injection, seek medical advice immediately and show the package insert to the physician. DO NOT DRIVE as sedation, loss of consciousness, and changes in blood pressure may occur.

Persons with cardiovascular disease should take special precautions to avoid any exposure to this product.

Pregnant women should exercise special caution to avoid exposure, as uterine contractions and decreased fetal blood pressure may occur.

Persons with known hypersensitivity to any of the ingredients should avoid contact with Zenalpha.

Caution should be exercised when handling sedated animals. Handling or any other sudden stimuli, including noise, may cause a defense reaction in an animal.

Animal Safety Warnings

Zenalpha should not be administered in the presence of pre-existing hypotension, hypoxia or bradycardia. Due to the pronounced cardiovascular effects of alpha2-adrenoceptor agonists, only clinically healthy dogs (American Society of Anesthesiologists [ASA] classes I and II) should be administered Zenalpha.

Zenalpha is not intended for use in cats. The use of Zenalpha in cats has been associated with hypotension.

PRECAUTIONS: Dogs should be monitored frequently during sedation for changes in heart rate, blood pressure, respiratory rate and body temperature.

In the event of hypoxia or apnea, supplemental oxygen should be administered.

Following administration of Zenalpha, a decrease in body temperature may occur and an external heat source may be needed to maintain body temperature.

The analgesic effect of Zenalpha will not last longer than the sedative effects. Additional analgesic(s) should be administered as needed.

Nervous, excited or agitated dogs with high levels of endogenous catecholamines may exhibit a reduced pharmacological response to Zenalpha (ineffectiveness). Therefore, allow the dog to rest quietly for 10 to 15 minutes after injection.

Zenalpha has only been evaluated in fasted dogs.

The concurrent use of anticholinergic medications and Zenalpha has not been evaluated.

Zenalpha may decrease serum glucose in healthy dogs and this effect may persist longer than sedation.

The safe use of Zenalpha has not been evaluated in dogs with hepatic or renal impairment, dogs younger than 4.5 months old, or dogs that are pregnant, lactating, or intended for breeding.

ADVERSE REACTIONS: The most common adverse reactions observed in the field study were decreased body temperature (not requiring external heat support), reduced respiratory rate, diarrhea, muscle tremor, signs of colitis, hypothermia (requiring external heat support).

To report suspected adverse reactions, for technical assistance, or to obtain a copy of the SDS, call Dechra at (866) 933-2472. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.

MANUFACTURED FOR:Dechra Veterinary Products
7015 College Boulevard, Suite 525
Overland Park, KS 66211 USA**Approved by FDA under NADA # 141-551**

Zenalpha is a registered trademark of Dechra Limited.

R 02 2023



17. Parasite prevalence maps—intestinal parasites—flea tapeworm—dog—2024. Companion Animal Parasite Council. Accessed October 30, 2025. <https://capcvet.org/maps/#/2024/all-year/flea-tapeworm/dog/united-states>
18. Gopinath D, Meyer L, Smith J, et al. Topical or oral fluralaner efficacy against flea (*Ctenocephalides felis*) transmission of *Dipylidium caninum* infection to dogs. *Parasit Vectors*. 2018;11(1):557. doi:10.1186/s13071-018-3140-x
19. Jesudoss Chelladurai J, Kifleyohannes T, Scott J, Brewer MT. Praziquantel resistance in the zoonotic cestode *Dipylidium caninum*. *Am J Trop Med Hyg*. 2018;99(5):1201-1205. doi:10.4269/ajtmh.18-0533
20. Gruntmeir J, Kelly M, Ramos RAN, Verocai GG. Cutaneous filarioid nematodes of dogs in the United States: are they emerging, neglected, or underdiagnosed parasites? *Front Vet Sci*. 2023;10:1128611. doi:10.3389/fvets.2023.1128611
21. Pfister K, Armstrong R. Systemically and cutaneously distributed ectoparasitocides: a review of the efficacy against ticks and fleas on dogs. *Parasit Vectors*. 2016;9(1):436. doi:10.1186/s13071-016-1719-7
22. McCoy C, Broce AB, Dryden MW. Flea blood feeding patterns in cats treated with oral nitenpyram and the topical insecticides imidacloprid, fipronil and selamectin. *Vet Parasitol*. 2008;156(3-4):293-301. doi:10.1016/j.jvetpar.2008.04.028
23. Zhou X, Hohman AE, Hsu WH. Current review of isoxazoline ectoparasitocides used in veterinary medicine. *J Vet Pharmacol Ther*. 2022;45(1):1-15. doi:10.1111/jvp.12959

Author**Brian Herrin**

Dr. Herrin is an associate professor at the University of Tennessee College of Veterinary Medicine. He obtained both his DVM and PhD degrees from Oklahoma State University. His current research focus is on the surveillance of vector-borne/emerging parasitic infections and the control of ticks and fleas on companion animals. Some of his recent interests are early effects of isoxazolines on ticks and pathogen transmission, surveillance of wildlife for *Echinococcus multilocularis*, and surveillance of flea-borne pathogens in home infestations. Although his research focus is mainly on ectoparasites, Dr. Herrin enjoys working with all parasites of veterinary importance through diagnostic service, teaching, and outreach opportunities.